US pharma firm Eli Lilly has signed a $2.75-billion deal with biotech firm InSilico Medicine for the development of drugs using AI, the latter said. Under the deal, both companies will collaborate on multiple research and development programmes using InSilico’s Pharma.AI platform. InSilico Medicine is eligible for $115 million in upfront payment, along with tiered royalties on future sales.